Shionogi’s respiratory syncytial virus (RSV) antiviral for adults has proven its ability to reduce viral load in a phase 2 ...

The 30-day risks of hospitalization were 17.5%, 15.9%, and 14.4% for COVID, influenza, and RSV, respectively, during the 2022 ...

While Sanofi’s immunology megablockbuster Dupixent predictably dominated the company’s sales charts in 2024, a new golden ...

RSV is usually contagious for three to eight days. A patient also may be contagious a day or two before experiencing symptoms ...

COVID-19 was associated with more severe disease outcomes than influenza or respiratory syncytial virus (RSV) during ...

Wales is past the peak of its flu season according to public health bosses. Cases of flu have caused chaos in Wales' ...

A new study is showing a policy change in 2016 related to the vaccination of some premature babies for RSV in Nova Scotia led ...

UPMC saw an increase in RSV cases in its health system, including in Lancaster County, a spokesperson said Jan. 7, especially ...

Sanofi’s jump in earnings comes with an increased emphasis on R&D and vaccines, plus an eye cast toward M&A to shore up its pipeline.

Tis the season—for the flu, COVID, stomach bugs, and other nasty viruses that can knock us down for several days, causing ...

U.S. surges of COVID-19, influenza, respiratory syncytial virus (RSV) and norovirus have collectively been dubbed a ...

At the start of every week, our team talks with local experts to unpack a wide range of nationwide health, safety, and ...